- Home
- OLOX vs APM Comparison
OLOX vs APM Comparison
Compare OLOX & APM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OLOX | APM |
|---|---|---|
| Founded | 2007 | 2010 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | RETAIL: Building Materials | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.1M | 5.6M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | OLOX | APM |
|---|---|---|
| Price | $5.18 | $0.70 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 26.5K | ★ 57.4K |
| Earning Date | 06-12-2026 | 03-31-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $1,628.82 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.45 | $0.60 |
| 52 Week High | $11.40 | $4.47 |
Technical Indicators
Market Signals| Indicator | OLOX | APM |
|---|---|---|
| Relative Strength Index (RSI) | 47.38 | 34.93 |
| Support Level | $4.59 | $0.65 |
| Resistance Level | $5.83 | $0.89 |
| Average True Range (ATR) | 0.53 | 0.05 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 43.29 | 42.86 |
Price Performance
Historical ComparisonAbout OLOX Olenox Industries Inc. Common Stock
Olenox Industries Inc is an industrial holding company focused on acquiring, operating, and scaling businesses that provide engineered solutions across industrial, energy, and infrastructure markets. Through its subsidiaries, it delivers high-quality modular and containerized systems designed for rapid deployment and long-term performance.
About APM Aptorum Group Limited
Aptorum Group Ltd is a clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. Aptorum's project pipeline includes SACT-1, a repurposed drug for the treatment of neuroblastoma, and ALS-4, a small molecule for the treatment of bacterial infections caused by Staphylococcus aureus, including but not limited to Methicillin-resistant Staphylococcus aureus (MRSA). Substantially all of the company's revenues are derived from within Hong Kong.